9Y4.F RYVU THERAPEUTICS ZY-40
- Market cap
- EUR 81.7M
- P/E
- -
- P/B
- 12.68x
- ROE
- -181.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 9Y4.F undervalued?
Graham numberThe Graham number of RYVU THERAPEUTICS ZY-40 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RYVU THERAPEUTICS ZY-40 fundamental analysis
No fundamental analysis for RYVU THERAPEUTICS ZY-40 yet.
RYVU THERAPEUTICS ZY-40 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RYVU THERAPEUTICS ZY-40
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kin…
Full company profileRYVU THERAPEUTICS ZY-40 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
RYVU THERAPEUTICS ZY-40 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 10.4M | 38.9M | 46.9M | 78.0M | 62.3M | 57.9M |
| Gross Profit | -3.37M | 21.5M | 29.3M | 58.4M | 47.5M | 42.6M |
| Operating Income | -80.4M | -69.5M | -97.4M | -122M | -97.2M | -58.3M |
| EBITDA | - | -65.2M | -81.0M | -96.8M | -81.3M | -33.9M |
| Net Income | -79.1M | -83.8M | -92.1M | -111M | -101M | -51.4M |
| EPS | -4.31 | -4.56 | -3.98 | -4.82 | -4.38 | -2.22 |
| Balance Sheet | ||||||
| Total Assets | 229M | 475M | 403M | 379M | 224M | 183M |
| Total Liabilities | 67.5M | 132M | 144M | 235M | 171M | 154M |
| Shareholders' Equity | 161M | 343M | 260M | 144M | 53.8M | 28.4M |
| Cash & Short-term Investments | 83.2M | 102M | 57.9M | 160M | 55.6M | 45.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -58.9M | 21.3M | -84.6M | -129M | -114M | -64.9M |
| Capital Expenditure | 12.0M | 9.29M | 8.58M | 5.90M | 7.47M | 1.80M |
| Free Cash Flow | -70.9M | 12.0M | -93.1M | -135M | -122M | -66.7M |
| Ratios | ||||||
| ROE | -49.0% | -24.4% | -35.5% | -77.4% | -188.0% | -181.2% |
| ROA | -34.6% | -17.6% | -22.8% | -29.4% | -45.1% | -28.2% |
| Net Profit Margin | -763.4% | -215.1% | -196.6% | -142.9% | -162.6% | -88.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
RYVU THERAPEUTICS ZY-40 dividends
RYVU THERAPEUTICS ZY-40 has not paid dividends in the last 5 fiscal years.
Who owns RYVU THERAPEUTICS ZY-40
- Insiders 35.02%
- Institutions 24.28%
- Public & others 40.70%
- Shares outstanding 23.1M
- Free float 16.0M
RYVU THERAPEUTICS ZY-40 company profile
- Company name
- RYVU THERAPEUTICS ZY-40
- Ticker
- 9Y4.F
- ISIN
- PLSELVT00013
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 228
- Fiscal year end
- December
- Address
- Leona Henryka Sternbacha 2, Kraków, Poland, 30-394
- Phone
- 48 12 314 0200
- Website
- ryvu.com
About RYVU THERAPEUTICS ZY-40
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company's early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu's STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
RYVU THERAPEUTICS ZY-40 management
7- Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.Founder, President of the Management Board & CEO
- Dr. Krzysztof Daniel Brzozka M.B.A., Ph.D.Executive VP, Chief Scientific Officer & VP of the Management Board
- Dr. Kamil Sitarz M.B.A., Ph.D.COO & Member of the Management Board
- Mr. Vatnak Vat-Ho M.B.A.Chief Business Officer & Member of Management Board
- Dr. Hendrik Nogai M.D.Chief Medical Officer & Member of Management Board
- Ms. Justyna ZoltekMember of the Management Board
- Ms. Paulina WolaninHuman Resources Manager